João Pedro Costa Apolinário
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
João Pedro Costa Apolinário has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Cançado Avelar
Mater Dei Hospital
2 shared publications - José Tadeu Campos de Avelar
Mater Dei Hospital
2 shared publications - Luisa Lazarino de Souza Campos
Mater Dei Hospital
2 shared publications - Maria Fernanda Sperotto Valadares Gontijo
Mater Dei Rede de Saúde, Brazil
2 shared publications - Anna Dias Salvador
Mater Dei Hospital
1 shared publication - Henrique Galvão
Mater Dei Rede de Saúde, Brazil
1 shared publication
Latest Publications
- Open Access
Epidemiological and clinicopathological parameters related to the neoadjuvant chemotherapy for breast cancer during the COVID-19 crisis
Introduction: Breast cancer, the second-leading cause of cancer-related deaths among women worldwide, is a complex and heterogeneous disease. Its socioeconomic aspects are recognized as determinants of clinical outcomes. The COVID-19 crisis negatively affected millions, particularly in impoverished macroregions like Brazil. Thus, influences on breast cancer patients’ journey may occur, particularly in the neoadjuvant settings, in which a coordinated and multidisciplinary approach is mandatory. The present study aimed to analyze the epidemiological and clinicopathological profile of breast cancer patients who underwent neoadjuvant chemotherapy during the pandemic in Brazil. Methods: This is a unicentric, retrospective, and descriptive cross-sectional study conducted by analyzing data obtained from electronic medical records of breast cancer patients who underwent neoadjuvant chemotherapy. Results: From March 2020 to December 2022, 55 patients underwent neoadjuvant chemotherapy. They presented an average age of 50.0 years (range 43.9–47.6). About 83.6% of the tumors were invasive ductal carcinomas, and the most prevalent molecular subtype was hormone receptor-positive. T2 tumors accounted for 50.9%, while compromised N1 axillary lymph nodes represented 52.7%. The most commonly used neoadjuvant chemotherapy combined anthracyclines, cyclophosphamide, and sequential taxane. Regarding postoperative pathological response, 42.2% showed a partial response after neoadjuvant treatment, and a complete pathological response of as high as 40.0% occurred. The luminal and hybrid luminal subtypes were those that achieved the greatest response to neoadjuvant therapy. The lack of pathological response was only found in the luminal molecular subtype. Conclusions: This study demonstrated the impacts of the COVID-19 pandemic on breast cancer patients’ journey. During this period of disruption in healthcare assistance, the disease presented at more advanced stages, but the pathologic complete response was higher than expected, and influences on chemotherapy decisions were not relevant. Overall, there were efforts to keep patients in the best breast cancer care.
Open AccessEpidemiological and clinicopathological parameters related to the neoadjuvant chemotherapy for breast cancer during the COVID-19 crisis
Introduction: Breast cancer, the second-leading cause of cancer-related deaths among women worldwide, is a complex and heterogeneous disease. Its socioeconomic aspects are recognized as determinants of clinical outcomes. The COVID-19 crisis negatively affected millions, particularly in impoverished macroregions like Brazil. Thus, influences on breast cancer patients’ journey may occur, particularly in the neoadjuvant settings, in which a coordinated and multidisciplinary approach is mandatory. The present study aimed to analyze the epidemiological and clinicopathological profile of breast cancer patients who underwent neoadjuvant chemotherapy during the pandemic in Brazil. Methods: This is a unicentric, retrospective, and descriptive cross-sectional study conducted by analyzing data obtained from electronic medical records of breast cancer patients who underwent neoadjuvant chemotherapy. Results: From March 2020 to December 2022, 55 patients underwent neoadjuvant chemotherapy. They presented an average age of 50.0 years (range 43.9–47.6). About 83.6% of the tumors were invasive ductal carcinomas, and the most prevalent molecular subtype was hormone receptor-positive. T2 tumors accounted for 50.9%, while compromised N1 axillary lymph nodes represented 52.7%. The most commonly used neoadjuvant chemotherapy combined anthracyclines, cyclophosphamide, and sequential taxane. Regarding postoperative pathological response, 42.2% showed a partial response after neoadjuvant treatment, and a complete pathological response of as high as 40.0% occurred. The luminal and hybrid luminal subtypes were those that achieved the greatest response to neoadjuvant therapy. The lack of pathological response was only found in the luminal molecular subtype. Conclusions: This study demonstrated the impacts of the COVID-19 pandemic on breast cancer patients’ journey. During this period of disruption in healthcare assistance, the disease presented at more advanced stages, but the pathologic complete response was higher than expected, and influences on chemotherapy decisions were not relevant. Overall, there were efforts to keep patients in the best breast cancer care.
- Open Access
The influence of germline mutations on breast cancer
The ability to evade protection mechanisms and uncontrolled cell growth can lead to the development of mutations, whether somatic or germline, and consequently to the dreaded diagnosis of cancer. Breast cancer is considered the most common type of cancer in women in several regions of Brazil, mainly in the South and Southeast, second only to non-melanoma skin cancer. Approximately 5% to 10% of neoplasms are related to germline alterations that lead to hereditary predisposition. There is evidence of an association with mutations in nine genes, the highest risk being breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2). Due to its epidemiological importance, in this narrative review we observed the main genetic mutations and syndromes associated with breast carcinoma, the recommendations for screening in high-risk patients, and the indication for genetic counseling. Bibliographic research on the PubMed and Cochrane databases and analysis of the Guidelines Breast Cancer Risk Reduction and Breast Cancer Screening and Diagnosis, from June 2022 to September 2023. In this review, we observed a greater influence of germline mutations on breast cancer related to the genes BRCA1, BRCA2, PALB2, PTEN, CDH1, STK11 and, in Brazil, considered a country of ethnic-racial diversity, to TP53. As cancer screening in the country is opportunistic, knowledge of germline mutations associated with breast cancer offers specific screening recommendations for high-risk patients, indications for genetic counseling, and guidelines for prophylactic surgery, in addition to impacting the formulation of public screening policies.
Open AccessThe influence of germline mutations on breast cancer
The ability to evade protection mechanisms and uncontrolled cell growth can lead to the development of mutations, whether somatic or germline, and consequently to the dreaded diagnosis of cancer. Breast cancer is considered the most common type of cancer in women in several regions of Brazil, mainly in the South and Southeast, second only to non-melanoma skin cancer. Approximately 5% to 10% of neoplasms are related to germline alterations that lead to hereditary predisposition. There is evidence of an association with mutations in nine genes, the highest risk being breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2). Due to its epidemiological importance, in this narrative review we observed the main genetic mutations and syndromes associated with breast carcinoma, the recommendations for screening in high-risk patients, and the indication for genetic counseling. Bibliographic research on the PubMed and Cochrane databases and analysis of the Guidelines Breast Cancer Risk Reduction and Breast Cancer Screening and Diagnosis, from June 2022 to September 2023. In this review, we observed a greater influence of germline mutations on breast cancer related to the genes BRCA1, BRCA2, PALB2, PTEN, CDH1, STK11 and, in Brazil, considered a country of ethnic-racial diversity, to TP53. As cancer screening in the country is opportunistic, knowledge of germline mutations associated with breast cancer offers specific screening recommendations for high-risk patients, indications for genetic counseling, and guidelines for prophylactic surgery, in addition to impacting the formulation of public screening policies.